Chiesi and Hephaï join forces to develop AI educational tool to improve inhaler use
REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease
• Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group
• REGEnLIFE’s technology shown to be safe and well-tolerated by patients
• Initial results open up new possibilities for development of brain-gut stimulation device for prevention and treatment of neurodegenerative diseases
Vygon Group takes part in UICC World Cancer Day 2021
Endo Tools Therapeutics secures €8 million ($9.5M) in Series D funding led by White Fund
Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty
CarThera starts phase I/II trial with Northwestern University to test SonoCloud-9 in recurrent glioblastoma
Robocath bolsters Strategic Committee with appointment of Chantal Le Chat
QuantaMatrix debuts on KOSDAQ on Dec 9 as IPO prices at high end, raising USD 40.2M
